Biostock has published an article on the development of advanced medical therapies in Sweden
On October 19, Biostock published an article on the development of advanced medical therapies in Sweden and how Sweden compares to an international comparison. The article mentions CombiGene together with other pharmaceutical companies such as AstraZeneca, Idogen, Xintela, Immunicum, NextCell Pharma and Verigraft. The full article can be read here:
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.